Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
ABEO vs CISS: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
ABEO Wins Head-to-Head Institutional Verdict (3–3 across 6 Pillars · 6–4 Matrix Metrics)
ABEO Overall Winner
6-Pillar Tally: ABEO 3 – 3 CISS
Matrix Metrics: ABEO 6 – 4 CISS
As of Nov 20, 2026, Abeona Therapeutics Inc. (ABEO) is the stronger overall head-to-head candidate over C3is Inc. (CISS) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Options & Positioning). ABEO carries a Unified Composite Score of 49.9/100 (HOLD) at $2.42 (18.7x Forward P/E, -186.1% operating margin), whereas CISS carries 33.6/100 (SELL) at $1.23 (N/M Forward P/E, 24.6% operating margin).
- Technical & Structure Timing Caution: ABEO is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 26.6); meanwhile CISS is in a Breakdown options structure phase (RSI 53.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About ABEO vs CISS
ABEO
Head-to-Head Winner
Abeona Therapeutics Inc. Common Stock
$2.42
-1.22% 1D
Market Cap
$167.4M
TTM Revenue
$39M
Forward P/E
18.7x
Beta / 30D Vol
0.60β · 149% Vol
Unified Composite Score
49.9
HOLD
Tech 60.0
Fund 61.0
Flow 67.0
Mom 55.0
Weinstein Technical Phase
Markdown · Sell / avoid
CISS
C3is Inc. Common Stock
$1.23
+4.24% 1D
Market Cap
$991,199
TTM Revenue
$36.2B
Forward P/E
N/M
Beta / 30D Vol
11.91β · 1054% Vol
Unified Composite Score
33.6
SELL
Tech 5.0
Fund 29.0
Flow 50.0
Mom 40.0
Weinstein Technical Phase
Neutral · Hold
6-Pillar Scorecard Institutional Category Breakdown (ABEO 3 – 3 CISS)
1. Valuation Multiples
ABEO
Forward P/E
18.7x
N/M
Trailing P/E
18.7x
N/M
PEG Ratio
N/M
N/M
EV / Revenue
3.0x
N/M
2. Growth & Scale
ABEO
Revenue Growth (YoY)
+2745.0%
+249.0%
Earnings Growth (YoY)
+0.0%
+193.3%
TTM Revenue (USD)
$39M
$36.2B
Market Cap
$167.4M
$991,199
3. Profitability & Quality
CISS
Gross Margin
-3.5%
68.1%
Operating Margin
-186.1%
24.6%
Net Profit Margin
-160.3%
27.4%
Return on Equity (ROE)
-42.1%
17.1%
4. Balance Sheet & Cash Flow
CISS
Cash Generation (TTM)
-$66M
$13.4B EBITDA
Cash Flow Margin
N/A
36.9% EBITDA Mgn
Net Cash / Leverage
$50M Net Cash
$384.31 Book/Sh · 17.1% ROE
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
ABEO
Options Structure Phase
BREAKDOWN
BREAKDOWN
Current IV / %ile
165.8% (27th %ile)
N/A (N/A)
Put/Call OI Skew
0.26x (Call-Skewed)
N/A
OBV Trend / Tech Phase
NEUTRAL · Markdown
NEUTRAL · Neutral
6. R&D & Supply-Chain Moat
CISS
OpEx & R&D Intensity
N/A
43.5% of Rev ($15.8B)
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Scale & Operating Efficiency Moat
Supply-Chain Role
Biotechnology Operator
Marine Shipping Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: ABEO (6) vs CISS (4)| Institutional Metric | ABEO | CISS | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $167.4M | $991,199 | ABEO | |
| Trailing P/E Ratio | 18.7x | N/M | ABEO | |
| Forward P/E Ratio | 18.7x | N/M | ABEO | |
| Revenue Growth (YoY) | +2745.0% | +249.0% | ABEO | |
| Operating Margin (TTM) | -186.1% | 24.6% | CISS | |
| Net Profit Margin | -160.3% | 27.4% | CISS | |
| Return on Equity (ROE) | -42.1% | 17.1% | CISS | |
| 52-Week Range Position | 6% ($2–$8) | 20% ($0–$6) | CISS | |
| Beta / 30D Volatility | 0.60β · 149% Vol | 11.91β · 1054% Vol | ABEO | |
| Unified Institutional Score | 49.9 / 100 (HOLD) | 33.6 / 100 (SELL) | ABEO | |
| Trailing 12M Revenue (USD) | $39M | $36.2B | Scale | |
| Gross Profit Margin (TTM) | -3.5% | 68.1% | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · 3.0x EV/Rev | N/M PEG · N/M EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$66M ($50M Net Cash) | $13.4B EBITDA ($384.31 Book/Sh · 17.1% ROE) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
CISS +181.09 pp
3M Horizon
CISS +7.2 pp
6M Horizon
CISS +7.63 pp
1Y Horizon
CISS +16.93 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | ABEO Revenue | CISS Revenue | ABEO Op. Margin | CISS Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2017 | $0M | N/A | -3325.7% | N/A | ABEO |
| FY2018 | $0M | N/A | -1940.2% | N/A | ABEO |
| FY2020 | $10M | N/A | -814.2% | N/A | ABEO |
| FY2021 | $0M | N/A | -2994.5% | N/A | ABEO |
| FY2022 | $0M | N/A | -3600.8% | N/A | ABEO |
| FY2023 | $0M | $30M | -1346.7% | 36.3% | CISS |
| FY2024 | N/A | $40M | N/A | 23.8% | CISS |
| FY2025 | $10M | $30M | -1536.9% | 3.9% | CISS |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
ABEO
BREAKDOWN
Current IV
165.8%
IV Percentile
27th %ile
Put/Call OI Skew
0.26x (Call-Skewed)
IV Regime
Balanced (25th–60th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
NEUTRAL
Exact ABEO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
CISS
BREAKDOWN
Current IV
N/A
IV Percentile
N/A
Put/Call OI Skew
N/A
IV Regime
Unclassified
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
Exact CISS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
ABEO Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
CISS Moat Profile
Scale & Operating Efficiency Moat
Marine Shipping Operator
OpEx & R&D Reinvestment
43.5% of Rev ($15.8B)
90D Engineering Disclosures
0 Published
Investor FAQ ABEO vs CISS Key Questions & Quantitative Answers
As of Nov 20, 2026, Abeona Therapeutics Inc. (ABEO) is the stronger overall head-to-head candidate over C3is Inc. (CISS) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Options & Positioning). ABEO carries a Unified Composite Score of 49.9/100 (HOLD) at $2.42 (18.7x Forward P/E, -186.1% operating margin), whereas CISS carries 33.6/100 (SELL) at $1.23 (N/M Forward P/E, 24.6% operating margin). Technical & Structure Timing Caution: ABEO is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 26.6); meanwhile CISS is in a Breakdown options structure phase (RSI 53.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
ABEO leads the Growth & Scale pillar: ABEO posts +2745.0% YoY revenue growth and +0.0% YoY earnings growth on $39M TTM revenue (-3.5% gross margin, -186.1% operating margin), compared with CISS at +249.0% YoY revenue growth and +193.3% YoY earnings growth on $36.2B TTM revenue (68.1% gross margin, 24.6% operating margin). Across the 8-period historical trajectory (FY2017 to FY2025), ABEO cumulative revenue shifted +0.0% while CISS shifted +0.0%. In operating R&D and SG&A reinvestment, ABEO deploys N/A (0 90-day corporate R&D disclosures) versus 43.5% of Rev ($15.8B) (0 disclosures) for CISS.
ABEO screens cheaper on headline valuation multiples. ABEO trades at 18.7x Forward P/E, 18.7x Trailing P/E, N/M PEG, and 3.0x EV/Revenue (unreported FCF margin), whereas CISS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (36.9% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ABEO (-42.1% ROE) versus CISS (17.1% ROE) capital efficiency.
In options market volatility and institutional positioning, ABEO carries 165.8% implied volatility (27th %ile, Balanced (25th–60th %ile)), a 0.26x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (0.60β · 149% Vol realized risk). By comparison, CISS carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (11.91β · 1054% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
CISS vs ABEO · Reverse Pair
ABEO vs ABUS
· Sector Peer
ABEO vs VSTM
· Sector Peer
CISS vs AKAN
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem
LLY vs NVO
· GLP-1 Biopharma
AVGO vs MRVL
· Custom ASIC & Networking